Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat and Ibrutinib in Relapsed/Refractory CLL and NHL
NCT03479268Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Apr 2018
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pevonedistat in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by City of Hope. Primary endpoints: Dose Limiting Toxicities at 42 days and Adverse Events. Started Apr 2018; status: active, not recruiting.
02
Drugs
pevonedistat
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03479268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03479268.